Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

NCT00737256 is registered in ClinicalTrials.gov with Paul Saenger as lead sponsor.

NCT NCT00737256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00737256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Lead sponsor
Paul Saenger
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2008
Completion date
May 31, 2014
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cocaine dependence, schizophrenia